- Oral presentation
- Open Access
Targeting the PI3K/AKT/MTOR pathway in KSHV-associated cancers
Infectious Agents and Cancer volume 4, Article number: O7 (2009)
Kaposi's sarcoma-associated herpesvirus (KSHV) is linked to three different human cancers: Kaposi's sarcoma (KS), primary effusion lymphoma (PEL) and multicentric Castleman's disease (MCD). We have previously reported that the PI3K/Akt/mTOR pathway is critical for the survival of KSHV-infected endothelial cells and B cells, and have demonstrated that Rapamycin/Sirolimus, an inhibitor of mTOR, can induce PEL cell death in vitro and in vivo (Sin et al., Blood. 2007. 109(5):2165–73). We have now extended these findings and demonstrate that therapeutic targeting of other members of the PI3K/Akt/mTOR signal transduction pathway can also induce cell death in PEL in vitro and inhibit tumor growth in murine xenograft models. Importantly, some of these novel drug candidates have passed clinical trials for other indications and can therefore be tested for efficacy against KS and AIDS-associated lymphomas.
Rights and permissions
Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/2.0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Bhatt, A., Bhende, P. & Damania, B. Targeting the PI3K/AKT/MTOR pathway in KSHV-associated cancers. Infect Agents Cancer 4 (Suppl 2), O7 (2009). https://doi.org/10.1186/1750-9378-4-S2-O7
- Cell Death
- Tumor Growth
- Therapeutic Target